Trinity BiotechTRIB +3.44%25 Days Payable is 230.67 as of Dec. 2025, which is 335% above its 10-year median of 53.06. GuruFocus rates TRIB with a GF Score™ of 25/100 and a GF Value™ of $0.73 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Trinity Biotech ranks better than 85.28% on this metric.
The historical rank and industry rank for Trinity Biotech's Days Payable or its related term are showing as below:
TRIB'
s Days Payable Range Over the Past 10 Years
Min: 48.76 Med: 53.06 Max: 202.63
Current: 202.63
During the past 13 years, Trinity Biotech's highest Days Payable was 202.63. The lowest was 48.76. And the median was 53.06.
TRIB's Days Payable is ranked better than 85.28% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs TRIB: 202.63
Trinity Biotech's Days Payable
increased
from Dec. 2024 (131.06) to Dec. 2025 (230.67).
It may suggest that Trinity Biotechdelayed paying its suppliers.
Trinity Biotech Days Payable Related Terms
Trinity Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Trinity Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Trinity Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (TRIB) has a Days Payable of 230.67 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Trinity Biotech and its competitors. This is 335% above median its historical median of 53.06. Over the past decade, Trinity Biotech's Days Payable has ranged from 48.76 to 202.63. According to the industry distribution chart, Trinity Biotech ranks #117 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 14.7%.
Is Trinity Biotech's Days Payable too high?
Trinity Biotech's current Days Payable of 230.67 is 335% above median its 10-year median of 53.06. Over the past 10 years, this metric has ranged from a low of 48.76 to a high of 202.63. The Medical Devices & Instruments industry median Days Payable is 67.87. Trinity Biotech's value of 230.67 is 239.9% above this industry median. Based on the distribution chart, Trinity Biotech ranks #117 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Trinity Biotech has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Days Payable compare to PMI and NXL?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #117 out of 795 companies for Days Payable. This places Trinity Biotech in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.87. Trinity Biotech's value of 230.67 is 239.9% above this benchmark. Historically, Trinity Biotech's own Days Payable has ranged from 48.76 to 202.63 over the past decade. While the company's 10-year median is 53.06 vs. the industry median of 67.87, Trinity Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trinity Biotech's current Days Payable of 230.67 is 239.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current Days Payable is 230.67, which is 335% above median its own 10-year median of 53.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.36 — trading 51.1% below its estimated fair value. The current Days Payable is 230.67, which is 335% above median its 10-year median of 53.06 and 239.9% above the Medical Devices & Instruments industry median of 67.87. Trinity Biotech's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Days Payable is 230.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $0.36 is trading 51.1% below its estimated GF Value™ of $0.73.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
Days Payable: 230.67 (335% above median its 10-year median of 53.06)
GF Value™: $0.73 vs. price of $0.36 (51.1% below fair value)
Industry Position: 239.9% above the Medical Devices & Instruments median (#117 of 795)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
25GF Score
Get the complete analysis for TRIB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
